Nordea Investment Management Reduces Johnson & Johnson Stake

Firm sells 649,409 shares of healthcare giant in Q4 2025

Mar. 24, 2026 at 9:38am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB, a major institutional investor, reduced its stake in Johnson & Johnson (NYSE: JNJ) by 10.6% in the fourth quarter of 2025, according to a recent SEC filing. The firm sold 649,409 shares of the healthcare company, leaving it with a remaining position of 5,460,452 shares worth approximately $1.13 billion.

Why it matters

Johnson & Johnson is a bellwether stock in the healthcare sector, and changes in ownership by major institutional investors can signal broader market trends or shifts in sentiment around the company. Nordea's decision to trim its JNJ holdings may reflect a broader reassessment of the stock's valuation or growth prospects by some investors.

The details

According to the SEC filing, Nordea Investment Management sold the 649,409 JNJ shares during the fourth quarter of 2025. This reduced the firm's total position in the company to 5,460,452 shares, or about 0.23% of Johnson & Johnson's outstanding stock. Nordea cited the sale as part of its regular portfolio management activities.

  • Nordea sold the 649,409 JNJ shares in Q4 2025.

The players

Nordea Investment Management AB

A major European asset management firm that oversees over $400 billion in client assets.

Johnson & Johnson

A multinational pharmaceutical and medical devices company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

Nordea's reduction in its Johnson & Johnson stake, while relatively small, could signal a broader shift in investor sentiment around the healthcare giant. However, the company remains a core holding for many institutional investors given its size, diversification, and market leadership position.